Recombinant human epidermal growth factor in the treatment of HFMD observed 120 cases of oral ulcers.doc

 PAGE \* MERGEFORMAT 10 Recombinant human epidermal growth factor in the treatment of HFMD observed 120 cases of oral ulcers [Abstract] Objective To observe the recombinant human epidermal growth factor (DRC due to peptide treatment of children with hand, foot and mouth disease with oral ulcers. Methods 120 cases of hand, foot and mouth disease with oral ulcers were randomly divided into control group, group and gold Xileisan for peptide group. control group were given conventional treatment Xileisan group were based on the surface of the ulcer spray Xileisan, gold for peptide group in the control group, based on the result of spraying the surface of the ulcer peptide. Observation 3 groups, eating to improve the situation, the number of days of oral ulcer and adverse drug reactions. Results Xileisan group (87.5% and gold by peptide group (92.5% of the total effective rate than the control group (60.0% (P lt;0.01, Gold for peptide group and healing time of oral ulcers (3.48 +-1.95d, time consuming to improve (2.40 +-1.43d, respectively, compared Xileisan group [(4.50 +-1.88d and (3.15 +-1.51d ] and the control group [(5.65 +-1.96d and (3.80 +-1.32d] shorter (P lt;0.05. Conclusion gold peptide in speeding up children because of foot and mouth disease and improvement of oral ulcer healing and eating situations with some success. [Keywords:] Children’s Hand, Foot and mouth disease, oral ulcers, epidermal growth factor HFMD (hand foot and mouth disease, HFMD epidemic in recent years, common in children [1 2], HFMD herpes angina stage, hands, feet and small blisters with typical rash associated with oral ulcers as the main symptoms, children oral ulcers often caused by pain and the pain got worse when eating and crying disturbed and refusal to eat, thus causing the decline in its extended duration of immunity. At present, no effective clinical treatment, this study was to use recombinant human epidermal growth factor (K due to peptide treatment of children w